Hydralyte

Q1 FY24 Quarterly Report and Appendix 4C: 43% Reduction in YoY Net Operating Cash Use to Record Low

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (Hydralyte North America or the Company) is pleased to provide the following update on its operational and financial performance for the three-month period ended 31 March 2024 (the “quarter”).


KEY HIGHLIGHTS

  • Net cash used in operating activities reduced to US$0.83m, a 43% decrease on PCP (Q1 FY23: US$1.45m) and down 27% on previous quarter (Q4 FY23: US$1.14m) – marking the seventh consecutive quarter of reductions
  • Net sales of US$2.17m – up 2% on the previous quarter (Q4 FY23: US$2.13m)
  • Unfilled orders from out of stock inventory for the quarter resulted in a net sales reduction of US$0.45m
  • After accounting for US$0.45m in unshipped orders due to out of stock inventory, underlying sales growth for Q1 FY24 increases to 23% on the prior quarter to US$2.62.
  • Gross margin increased 3ppt on PCP (Q1 FY23: 47%) to 50%, increasing to 56% when adjusted for once-off inventory writedowns
  • Gross margin negatively impacted by inventory write-off of $0.13m in the shift towards the high profitability SKUs, reducing margin by 6ppt from 56% to 50%
  • Marketing costs as a percentage of net revenue decreased to 37% - down from 48% in Q1 FY23
  • Amended funding agreement signed with Pure Asset Management providing additional funds to the Company
  • New funds will be used in order to seek to implement a sale of the Company for the benefit of stakeholders
  • Continued execution of stated strategy to reduce cash expenditure and extend cash reserves
Financial overview:

During the quarter, the Company continued to deliver on its stated strategy to maintain sales growth with a material reduction in net operating expenditure. This focus on cash preservation resulted in net cash used in operating activities decreasing to US$0.83m, highlighting a 43% reduction on the previous corresponding period (PCP) (Q1 FY23: US$1.45m) and a 27% reduction on the previous quarter (Q4 FY23: US$1.147m).

Revenue for the quarter increased by 2% on the previous quarter (Q4 FY23: US$2.13m) to US$2.17m. Quarterly revenue was impacted by inventory issues during January, which accounted for approximately US$0.45m in unshipped orders. Adjusted net sales after accounting for these unshipped orders resulted in a 23% increase on the previous quarter.

The Company has rectified these inventory issues and has been back in stock on key products since mid-quarter. The Company expects only a minor impact from out-of-stocks during Q2 FY2024.

Canadian operations continue to show strong growth and underpinned the Company’s growth trajectory in the March quarter. Sales in the territory for the quarter increased 7% on PCP (Q1 FY2023: US$1.33m) to US$1.43m. Canada ecommerce sales increased to 52% on PCP to US$0.49m.

With the strategy of prioritising profitability, the Company increased focus on ecommerce and Canadian retail growth. With less focus on US retail, US sales for quarter decreased 38% on PCP (Q1 FY2023: US$1.20m) to US$0.74m.

In the shift to profitable Amazon growth, US ecommerce revenue decreased 5% on PCP (Q1 FY2023: US$0.67m) to US$0.64m. Subsequent to quarter end, US ecommerce has shifted to profitable year-on-year growth.

US bricks and mortar revenue decreased 82% on PCP (Q1 FY2023: US$0.54m) to US$0.10m. This was largely due to large US retailer, Rite Aid decreasing orders due to restructuring following its bankruptcy in late 2023. The reduction in Rite Aid revenue resulted in a US$0.25m decrease on PCP. Rite Aid bankruptcy plus trailing net sales deductions caused a one-time negative net sales impact of US$(0.08m).


Click here for the full ASX Release

This article includes content from The Hydration Pharmaceuticals Company Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

HPC:AU
Hydralyte International

Hydralyte International Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.

At this point, their work is far from finished — Fortune Business Insights projects that the global oncology market will increase at a compound annual growth rate of 11.3 percent to reach US$518.25 billion in 2032.

As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on oncology drugs and testing.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Limited (ASX: RAD) – Reinstatement to Quotation

Description

The suspension of trading in the securities of Radiopharm Theranostics Limited (‘RAD’) will be lifted immediately following the release by RAD of an announcement regarding its capital raising.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Completes A$70 Million Placement

Radiopharm Theranostics Limited (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, has received firm commitments to raise approximately A$70.0 million (before costs) by way of a placement (the Placement) comprised of international and Australian institutional and industry investors, including Lantheus Holdings (“Lantheus”) and specialist US healthcare investors.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Receives Strategic Investment for up to A$18 million

Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or the Company), a developer of diagnostic and therapeutic radiopharmaceutical products, has entered into strategic agreements with Lantheus Holdings, Inc. (LNTH.NASDAQ), a leading radiopharmaceutical-focused company, and its affiliates (Lantheus). Lantheus has agreed to make an initial equity investment of A$7.5 million (US$4.99 million) and will have an option to invest a further A$7.5 million (US$5 million) within 6 months on the same terms. Additionally, Radiopharm has agreed to transfer two of its early preclinical assets to Lantheus for A$3.0 million (US$2.0 million) pursuant to a separate transfer and development agreement.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Limited (ASX: RAD) – Trading Halt

Description

The securities of Radiopharm Theranostics Limited (‘RAD’) will be placed in trading halt at the request of RAD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 24 June 2024 or when the announcement is released to the market.

Keep reading...Show less
Hydralyte International

Hydralyte International Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×